| 1 | A global action agenda for turning the tide on fatty liver disease | 10.0 | 59 | Citations (PDF) |
| 2 | Active alcohol consumption is associated with acute-on-chronic liver failure in Hispanic patients | 0.5 | 6 | Citations (PDF) |
| 3 | Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes | 2.9 | 80 | Citations (PDF) |
| 4 | From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women | 0.4 | 31 | Citations (PDF) |
| 5 | Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon | 0.9 | 5 | Citations (PDF) |
| 6 | Review article: Current indications and selection criteria for early liver transplantation in severe alcohol‐associated hepatitis | 4.0 | 8 | Citations (PDF) |
| 7 | Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis | 4.6 | 17 | Citations (PDF) |
| 8 | Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration? | 2.3 | 1 | Citations (PDF) |
| 9 | Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019 | 10.0 | 32 | Citations (PDF) |
| 10 | Reply to: “The synergism of public health policies and social work may reduce mortality from cancer, liver disease and cardiovascular disease” | 2.9 | 0 | Citations (PDF) |
| 11 | Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy | 3.3 | 3 | Citations (PDF) |
| 12 | Active alcohol consumption is associated with acute-on-chronic liver failure in Hispanic patients | 0.1 | 0 | Citations (PDF) |
| 13 | A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD | 3.4 | 7 | Citations (PDF) |
| 14 | Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality | 4.6 | 8 | Citations (PDF) |
| 15 | Review article: Oesophageal disorders in chronic liver disease | 4.0 | 6 | Citations (PDF) |
| 16 | Racial and ethnic disparities in the natural history of alcohol‐associated liver disease in the United States | 4.2 | 11 | Citations (PDF) |
| 17 | MASLD: a disease in flux | 40.1 | 7 | Citations (PDF) |
| 18 | Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis | 4.6 | 2 | Citations (PDF) |
| 19 | Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria | 5.7 | 34 | Citations (PDF) |
| 20 | Nonalcoholic Fatty Liver Disease in Latin America and Australia | 3.6 | 8 | Citations (PDF) |
| 21 | Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder | 6.1 | 49 | Citations (PDF) |
| 22 | Current and emerging therapies for alcohol-associated hepatitis | 1.6 | 8 | Citations (PDF) |
| 23 | Early living donor liver transplantation for alcohol-associated hepatitis | 1.2 | 19 | Citations (PDF) |
| 24 | Measuring NAFLD models of care | 40.1 | 8 | Citations (PDF) |
| 25 | A global research priority agenda to advance public health responses to fatty liver disease | 2.9 | 100 | Citations (PDF) |
| 26 | The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease | 40.1 | 136 | Citations (PDF) |
| 27 | Inverse correlation between vitamin D and <scp>CRP</scp> levels in alopecia areata: A pilot study | 2.0 | 4 | Citations (PDF) |
| 28 | New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease | 10.0 | 30 | Citations (PDF) |
| 29 | Liver transplantation in Latin America: reality and challenges | 2.7 | 5 | Citations (PDF) |
| 30 | Role of Prophylactic Antibiotics in Patients with Severe Alcohol-related Hepatitis | 0.8 | 3 | Citations (PDF) |
| 31 | Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation | 2.4 | 6 | Citations (PDF) |
| 32 | Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis | 0.8 | 7 | Citations (PDF) |
| 33 | Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis | 6.1 | 38 | Citations (PDF) |
| 34 | LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV | 1.2 | 4 | Citations (PDF) |
| 35 | Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA | 2.2 | 17 | Citations (PDF) |
| 36 | Sending an SOS: Healing the Liver with the Bone Marrow | 2.2 | 0 | Citations (PDF) |
| 37 | Gut Microbiota-Related Clinical Events and Therapeutic Interventions in Alcohol-Associated Liver Disease 2022, , 129-145 | | 0 | Citations (PDF) |
| 38 | Vaccination against <scp>COVID</scp>‐19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis | 4.2 | 6 | Citations (PDF) |
| 39 | Current Medical Treatment for Alcohol-Associated Liver Disease | 0.8 | 55 | Citations (PDF) |
| 40 | Alcohol Consumption: Medical Implications, the Liver and Beyond | 1.9 | 92 | Citations (PDF) |
| 41 | The Mortality Index for Alcohol-Associated Hepatitis: A Novel Prognostic Score | 2.5 | 11 | Citations (PDF) |
| 42 | The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas | 12.1 | 53 | Citations (PDF) |
| 43 | Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate | 1.9 | 13 | Citations (PDF) |
| 44 | Public Health Measures and Prevention of Alcohol-Associated Liver Disease | 0.8 | 30 | Citations (PDF) |
| 45 | Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement | 1.0 | 33 | Citations (PDF) |
| 46 | Early Diagnosis and Prevention of Infections in Cirrhosis | 3.4 | 32 | Citations (PDF) |
| 47 | SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study | 2.7 | 10 | Citations (PDF) |
| 48 | Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective | 1.6 | 2 | Citations (PDF) |
| 49 | Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy | 2.4 | 0 | Citations (PDF) |
| 50 | Nutrition in Alcohol-Related Liver Disease | 0.9 | 0 | Citations (PDF) |
| 51 | Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management | 0.4 | 15 | Citations (PDF) |
| 52 | Alcohol-Associated Hepatitis | 25.1 | 190 | Citations (PDF) |
| 53 | Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group | 6.1 | 96 | Citations (PDF) |
| 54 | The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis | 10.0 | 55 | Citations (PDF) |
| 55 | Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis | 10.0 | 71 | Citations (PDF) |
| 56 | Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action | 10.0 | 120 | Citations (PDF) |
| 57 | The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease | 12.1 | 122 | Citations (PDF) |
| 58 | Triple‐Phase Computed Tomography May Replace Dual‐Energy X‐ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates | 2.6 | 3 | Citations (PDF) |
| 59 | Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management | 3.5 | 81 | Citations (PDF) |
| 60 | Pulsatile Epigastric Mass and Liver Masses in a 38-Year-Old Patient With Splenomegaly Since Childhood | 1.0 | 0 | Citations (PDF) |
| 61 | XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC | 3.0 | 7 | Citations (PDF) |
| 62 | Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis | 1.7 | 30 | Citations (PDF) |
| 63 | Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1β levels | 3.7 | 3 | Citations (PDF) |
| 64 | Diagnosis of Alcohol-Associated Hepatitis | 3.6 | 7 | Citations (PDF) |
| 65 | COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence | 2.2 | 15 | Citations (PDF) |
| 66 | Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study | 2.9 | 123 | Citations (PDF) |
| 67 | Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis | 14.2 | 83 | Citations (PDF) |
| 68 | Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics | 4.0 | 78 | Citations (PDF) |
| 69 | Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity | 3.4 | 86 | Citations (PDF) |
| 70 | Impact of Public Health Policies on Alcohol‐Associated Liver Disease in Latin America: An Ecological Multinational Study | 10.0 | 67 | Citations (PDF) |
| 71 | Impact of COVID-19 on liver transplant recipients–A systematic review and meta-analysis | 8.3 | 67 | Citations (PDF) |
| 72 | Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV | 6.6 | 24 | Citations (PDF) |
| 73 | Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030? | 1.4 | 10 | Citations (PDF) |
| 74 | P-64 THE ALCOHOL-ASSOCIATED LIVER DISEASE PARADOX IN CHILE: AN ASSESSMENT WITH DATA FROM THE NATIONAL HEALTH SURVEY (ENS 2016-2017) | 1.2 | 1 | Citations (PDF) |
| 75 | NAFLD: Challenges and opportunities to address the public health problem in Latin America | 1.2 | 35 | Citations (PDF) |
| 76 | P-30 IMPACT OF PUBLIC HEALTH POLICIES ON ALCOHOL-ASSOCIATED LIVER DISEASE IN LATIN AMERICA: AN ECOLOGICAL MULTI-NATIONAL STUDY | 1.2 | 0 | Citations (PDF) |
| 77 | P-63 TRENDS IN HOSPITALIZATION AND MORTALITY IN HOSPITALIZED PATIENTS WITH ALCOHOLIC HEPATITIS IN CHILE | 1.2 | 0 | Citations (PDF) |
| 78 | P-41 TRENDS IN HOSPITALIZATION, CHARACTERISTICS AND MORTALITY OF HOSPITALIZED PATIENTS WITH CIRRHOSIS IN CHILE | 1.2 | 0 | Citations (PDF) |
| 79 | Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice | 1.2 | 12 | Citations (PDF) |
| 80 | Advancing the global public health agenda for NAFLD: a consensus statement | 40.1 | 596 | Citations (PDF) |
| 81 | Socioeconomic inequalities in the incidence of alcohol-related liver disease in the Latin American context | 5.9 | 6 | Citations (PDF) |
| 82 | Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation | 40.1 | 95 | Citations (PDF) |
| 83 | Resumen ejecutivo: Enfermedad por hígado graso no alcohólico en sujetos con diabetes mellitus tipo 2: Postura conjunta de la Asociación Chilena de Hepatología (ACHHEP) y la Sociedad Chilena de Diabetología (SOCHIDIAB) | 0.2 | 2 | Citations (PDF) |
| 84 | Factors Having an Impact on Relapse and Survival in Transplant Recipients With Alcohol-Induced Liver Disease | 2.2 | 15 | Citations (PDF) |
| 85 | Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high‐risk gastro‐oesophageal varices in a Chilean cohort | 4.2 | 21 | Citations (PDF) |
| 86 | An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis | 10.0 | 174 | Citations (PDF) |
| 87 | Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease | 1.2 | 109 | Citations (PDF) |
| 88 | Higher Frequency of Hospital-Acquired Infections but Similar In-Hospital Mortality Among Admissions With Alcoholic Hepatitis at Academic vs. Non-academic Centers | 3.0 | 7 | Citations (PDF) |
| 89 | Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities | 2.7 | 110 | Citations (PDF) |
| 90 | Alcohol‐Related Liver Disease in Latin America: Local Solutions for a Global Problem | 1.4 | 18 | Citations (PDF) |
| 91 | Are We Really Taking Care of Alcohol‐Related Liver Disease in Latin America? | 1.4 | 15 | Citations (PDF) |
| 92 | GIPC-Regulated IGFBP-3 Promotes HSC Migration In Vitro and Portal Hypertension In Vivo Through a β1-Integrin Pathway | 5.5 | 30 | Citations (PDF) |
| 93 | Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells | 4.2 | 37 | Citations (PDF) |
| 94 | Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy | 4.8 | 52 | Citations (PDF) |
| 95 | Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19 | 4.0 | 216 | Citations (PDF) |
| 96 | Metabolomic Biomarkers are Associated With Mortality in Patients With Cirrhosis Caused By Primary Biliary Cholangitis Or Primary Sclerosing Cholangitis | 2.0 | 9 | Citations (PDF) |
| 97 | Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12 | 2.9 | 58 | Citations (PDF) |
| 98 | Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles | 4.2 | 53 | Citations (PDF) |
| 99 | Hospitalizations for Acute on Chronic Liver Failure at Academic Compared to Non-academic Centers Have Higher Mortality | 2.2 | 17 | Citations (PDF) |
| 100 | Quantitative assessment of portal hypertension with bi-parametric dual-frequency hepatic MR elastography in mouse models | 3.9 | 5 | Citations (PDF) |
| 101 | High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data | 4.7 | 63 | Citations (PDF) |
| 102 | Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH 2020, , 225-236 | | 0 | Citations (PDF) |
| 103 | Letter: elevated liver enzymes and outcomes in COVID Authors' reply | 4.0 | 0 | Citations (PDF) |
| 104 | Old Remedies to Heal the Liver: Novel Effects of Digoxin in Hepatic Sterile Inflammation | 10.0 | 2 | Citations (PDF) |
| 105 | Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations | 2.4 | 41 | Citations (PDF) |
| 106 | Liver Dysfunction as a Novel Player in Alzheimer’s Progression: Looking Outside the Brain | 4.1 | 134 | Citations (PDF) |
| 107 | Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis | 14.2 | 180 | Citations (PDF) |
| 108 | 462 – Circulating Extracellular Vesicles and Sphingolipids Cargo are Highly Accurate Novel Biomarkers for Diagnosis of Alcoholic Hepatitis | 1.0 | 3 | Citations (PDF) |
| 109 | UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications | 1.0 | 76 | Citations (PDF) |
| 110 | Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH) | 1.2 | 104 | Citations (PDF) |
| 111 | Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis | 5.5 | 73 | Citations (PDF) |
| 112 | Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease | 31.9 | 489 | Citations (PDF) |
| 113 | The evolving role of liver biopsy in non-alcoholic fatty liver disease | 1.2 | 30 | Citations (PDF) |
| 114 | Impact of Pre- and Post-liver Transplant Addiction Treatment and AA Attendance on Outcomes for Recipients with Alcoholic Liver Disease | 2.0 | 6 | Citations (PDF) |
| 115 | 804 - Integrin Based Angiocrine Signals Recruit Neutrophils to Drive Portal Hypertension in Congestive Hepatopathy | 1.0 | 0 | Citations (PDF) |
| 116 | 892 - Transcriptional Dysregulation of Inflammatory Gene Networks in Alcoholic Hepatitis is Associated with Genomewide Reconfiguration of Epigenetic States | 1.0 | 1 | Citations (PDF) |
| 117 | Sa1460 - Extracellular Vesicle C16 Ceramide and S1P Content in Alcoholic Hepatitis Correlates with Disease Severity and Resolution | 1.0 | 2 | Citations (PDF) |
| 118 | Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation | 4.5 | 25 | Citations (PDF) |
| 119 | Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population | 0.1 | 3 | Citations (PDF) |
| 120 | Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis | 3.7 | 82 | Citations (PDF) |
| 121 | Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences | 0.9 | 3 | Citations (PDF) |
| 122 | Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena | 0.5 | 12 | Citations (PDF) |
| 123 | Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects | 2.8 | 81 | Citations (PDF) |
| 124 | Nuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC) | 0.2 | 3 | Citations (PDF) |
| 125 | Bile Acids and Portal Hypertension | 1.2 | 15 | Citations (PDF) |
| 126 | Bile Acids in Cholestasis and its Treatment | 1.2 | 41 | Citations (PDF) |
| 127 | Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg | 4.5 | 197 | Citations (PDF) |
| 128 | Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms | 5.5 | 19 | Citations (PDF) |
| 129 | Consenso chileno de prevención, diagnóstico y tratamiento de la diarrea asociada a Clostridium difficile | 0.2 | 8 | Citations (PDF) |
| 130 | Aumento aislado y sostenido de aspartato aminotransferasa por presencia de macroenzimas: Caso clínico | 0.2 | 5 | Citations (PDF) |
| 131 | Statins and portal hypertension: A tale of two models | 10.0 | 12 | Citations (PDF) |
| 132 | Achieving protection against HBV in HIV patients: Finding the best strategy | 3.4 | 1 | Citations (PDF) |
| 133 | CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study | 3.3 | 68 | Citations (PDF) |
| 134 | Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus | 2.4 | 12 | Citations (PDF) |
| 135 | Evaluación para el aprendizaje: experiencia en un curso teórico de pregrado en medicina | 0.2 | 7 | Citations (PDF) |
| 136 | Incorporación de paciente virtual en portafolio de estudiantes de medicina de pregrado | 0.2 | 5 | Citations (PDF) |
| 137 | Evaluación de docentes clínicos de Postgrado: desarrollo y propiedades psicométricas del instrumento MEDUC-PG14 | 0.2 | 8 | Citations (PDF) |
| 138 | Black hairy tongue during interferon therapy for hepatitis C | 1.2 | 12 | Citations (PDF) |
| 139 | Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach | 1.2 | 5 | Citations (PDF) |
| 140 | Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension | 2.0 | 6 | Citations (PDF) |
| 141 | Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review | 4.7 | 54 | Citations (PDF) |
| 142 | Cetoacidosis diabética: Casuística 2008-2012, epidemiología y fisiopatología | 0.2 | 2 | Citations (PDF) |
| 143 | Effects of bile acid sequestration on hepatic steatosis in obese mice | 1.2 | 7 | Citations (PDF) |
| 144 | Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion | 3.7 | 26 | Citations (PDF) |
| 145 | Management of<i>Helicobacter pylori</i>infection in Latin America: A Delphi technique-based consensus | 4.7 | 28 | Citations (PDF) |
| 146 | Hepatic encephalopathy in a liver transplant recipient with stable liver function | 10.0 | 7 | Citations (PDF) |
| 147 | Niveles séricos de alanino-aminotransferasa en población chilena: análisis de los resultados de la encuesta nacional de salud 2009-2010 | 0.2 | 0 | Citations (PDF) |
| 148 | Liver Disease 2012, , 289-296 | | 2 | Citations (PDF) |
| 149 | Reanimación cardiopulmonar básica: conocimiento teórico, desempeño práctico y efectividad de las maniobras en médicos generales | 0.2 | 14 | Citations (PDF) |
| 150 | Aquaporin-1 Promotes Angiogenesis, Fibrosis, and Portal Hypertension Through Mechanisms Dependent on Osmotically Sensitive MicroRNAs | 3.5 | 68 | Citations (PDF) |
| 151 | Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease | 1.2 | 14 | Citations (PDF) |
| 152 | Early warning of liver disease in diabetics | 1.2 | 4 | Citations (PDF) |
| 153 | Bacteriemia por Streptococcus pyogenes: Presentación de un caso clínico con aparición tardía de neumonía | 0.2 | 1 | Citations (PDF) |
| 154 | Effects of Japanese herbal medicine inchin-ko-to on endotoxin-induced cholestasis in the rat | 1.2 | 16 | Citations (PDF) |
| 155 | Mild hypothermia does not affect liver regeneration after partial hepatectomy in mice | 4.2 | 8 | Citations (PDF) |
| 156 | Colorectal adenomas and MAFLD: a cross-sectional study in a hispanic screening cohort 0, , | | 4 | Citations (PDF) |
| 157 | Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease 0, 4, | | 4 | Citations (PDF) |
